Protalix BioTherapeutics, Inc. (PLX)
Data as of , from SEC Form 4 filings.
See up to 3 months of PLX. The 7-day demo opens the 1M and 3M ranges and puts PLX on your watchlist.
Start 7-day demoLatest PLX insider trades
About Protalix BioTherapeutics, Inc. (PLX)
Protalix BioTherapeutics, Inc. is an SEC registrant, filing under CIK 0001006281, classified as biological products (no diagnostic substances). We track it alongside the rest of the Health Care sector.
PLX Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 18 | 826,500 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
PLX insider transactions (Form 4)
3820 Form 4 filings on record, the earliest from Aug 12, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aharon Schwartz - Director | Grant or award | Stock Options (Right to Buy) | 17,000 | $0.00 | - | |
| Aharon Schwartz - Director | Grant or award | Restricted Stock Units | 8,500 | $0.00 | - | |
| Yaron Naos - Officer | Grant or award | Stock Option (Right to Buy) | 112,000 | $0.00 | - | |
| Yaron Naos - Officer | Grant or award | Restricted Stock Units | 56,000 | $0.00 | - | |
| Gwen A. Melincoff - Director | Grant or award | Stock Options (Right to Buy) | 17,000 | $0.00 | - | |
| Gwen A. Melincoff - Director | Grant or award | Restricted Stock Units | 8,500 | $0.00 | - | |
| Christian Elze - Director | Grant or award | Stock Options (Right to Buy) | 17,000 | $0.00 | - | |
| Christian Elze - Director | Grant or award | Restricted Stock Units | 8,500 | $0.00 | - | |
| Pol F. Boudes - Director | Grant or award | Stock Options (Right to Buy) | 17,000 | $0.00 | - | |
| Pol F. Boudes - Director | Grant or award | Restricted Stock Units | 8,500 | $0.00 | - | |
| Amos Bar-Shalev - Director | Grant or award | Stock Options (Right to Buy) | 17,000 | $0.00 | - | |
| Amos Bar-Shalev - Director | Grant or award | Restricted Stock Units | 8,500 | $0.00 | - | |
| Dror Bashan - Officer | Grant or award | Stock Option (Right to Buy) | 320,000 | $0.00 | - | |
| Dror Bashan - Officer | Grant or award | Restricted Stock Units | 160,000 | $0.00 | - | |
| Zvi Shmuel Ben - Director | Grant or award | Stock Options (Right to Buy) | 17,000 | $0.00 | - | |
| Zvi Shmuel Ben - Director | Grant or award | Restricted Stock Units | 8,500 | $0.00 | - | |
 Eliot Forster - Director | Grant or award | Stock Options (Right to Buy) | 17,000 | $0.00 | - | |
| Eliot Forster - Director | Grant or award | Restricted Stock Units | 8,500 | $0.00 | - | |
| Amos Bar-Shalev | Open-market sale | Common Stock | 168 | $1.87 | $314 | |
| Eliot Forster | Grant or award | Common Stock | 7,500 | - | - | |
| Eliot Forster | Grant or award | Stock Options (Right to Buy) | 15,000 | $0.00 | - | |
| Christian Elze | Grant or award | Common Stock | 7,500 | - | - | |
| Christian Elze | Grant or award | Stock Options (Right to Buy) | 15,000 | $0.00 | - | |
| Gwen A. Melincoff | Grant or award | Common Stock | 7,500 | - | - | |
| Gwen A. Melincoff | Grant or award | Stock Options (Right to Buy) | 15,000 | $0.00 | - | |
| Pol F. Boudes | Grant or award | Common Stock | 7,500 | - | - | |
| Pol F. Boudes | Grant or award | Stock Options (Right to Buy) | 15,000 | $0.00 | - | |
| Aharon Schwartz | Grant or award | Common Stock | 7,500 | - | - | |
| Aharon Schwartz | Grant or award | Stock Options (Right to Buy) | 15,000 | $0.00 | - | |
| Zvi Shmuel Ben | Grant or award | Common Stock | 7,500 | - | - | |
| Zvi Shmuel Ben | Grant or award | Stock Options (Right to Buy) | 15,000 | $0.00 | - | |
| Amos Bar-Shalev | Grant or award | Common Stock | 7,500 | - | - | |
| Amos Bar-Shalev | Grant or award | Stock Options (Right to Buy) | 15,000 | $0.00 | - | |
| Yaron Naos - Officer | Grant or award | Common Stock | 25,000 | - | - | |
| Yaron Naos - Officer | Grant or award | Stock Option (Right to Buy) | 50,000 | $0.00 | - | |
| Dror Bashan - Officer | Grant or award | Common Stock | 195,000 | - | - | |
| Dror Bashan - Officer | Grant or award | Stock Option (Right to Buy) | 340,000 | $0.00 | - | |
| Aharon Schwartz | Open-market purchase | Common Stock | 129,000 | $1.60 | $206K |
PLX insider trading FAQ
What is the latest insider trade for PLX?
Protalix BioTherapeutics, Inc. (PLX) had 9 insider filings in the last 90 days, with the most recent on 2026-09-09. The full record for PLX runs to 20 Form 4 filings, the earliest from 2025-08-12. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying PLX stock?
No insider purchases of PLX were filed in the last 90 days. 1 purchase is on record for this company.
How many insiders are selling PLX stock?
No insider sales of PLX were filed in the last 90 days. 1 sale is on record for this company.
Where can I see PLX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects PLX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Aharon Schwartz view on EDGAR
- - Yaron Naos view on EDGAR
- - Gwen A. Melincoff view on EDGAR
- - Christian Elze view on EDGAR
- - Pol F. Boudes view on EDGAR
- - Amos Bar-Shalev view on EDGAR
- - Dror Bashan view on EDGAR
- - Zvi Shmuel Ben view on EDGAR
- - Eliot Forster view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where PLX's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow PLX with a 7-day demo
- PLX on your watchlist
- Every PLX Form 4 filing on record
- Up to 3 months of PLX price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
